Dysferlinopathies

Handbook of Clinical Neurology

Volumn 101, Issue , 2011, Pages 111-118

  Amato, Anthony A ^a   Brown, Robert H ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSF PROTEIN, HUMAN; MEMBRANE PROTEIN; MUSCLE PROTEIN;

ANIMAL; BOOK; GENETICS; HUMAN; MUSCLE DISEASE; MUTATION;

ANIMALS; HUMANS; MEMBRANE PROTEINS; MUSCLE PROTEINS; MUSCULAR DISEASES; MUTATION;

EID: 79954484329     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-08-045031-5.00007-4     Document Type: Book

References (57)

1. Anderson L.V., Harrison R.M., Pogue R., et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord 2000, 10:553-559.
2. Bansal D., Miyake K., Vogel S.S., et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172.
3. Bashir R., Britton S., Strachan T. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998, 20:37-42.
4. Bernard C.C., Carnegie P.R. Experimental autoimmune encephalomyelitis in mice: immunologic response to mouse spinal cord and myelin basic proteins. J Immunol 1975, 114:1537-1540.
5. Bittner R.E., Anderson L.V., Burkhardt E., et al. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 1999, 23:141-142.
6. Brummer D., Walter M.C., Palmbach M., et al. Long-term MRI and clinical follow-up of symptomatic and presymptomatic carriers of dysferlin gene mutations. Acta Myol 2005, 24:6-16.
7. Cagliani R., Magri F., Toscano A., et al. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Hum Mutat 2005, 26:283.
8. Cenacchi G., Fanin M., De Giorgi L.B., et al. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol 2005, 58:190-195.
9. Chrobakova T., Hermanova M., Kroupova I., et al. Mutations in Czech LGMD2A patients revealed by analysis of calpain3 mRNA and their phenotypic outcome. Neuromuscul Disord 2004, 14:659-665.
10. Diers A., Carl M., Stoltenburg-Didinger G., et al. Painful enlargement of the calf muscles in limb girdle muscular dystrophy type 2B (LGMD2B) with a novel compound heterozygous mutation in DYSF. Neuromuscul Disord 2007, 17:157-162.
11. Fanin M., Pegoraro E., Matsuda-Asada C., et al. Calpain-3 and dysferlin protein screening in patients with limb-girdle dystrophy and myopathy. Neurology 2001, 56:660-665.
12. Fischer D., Walter M.C., Kesper K., et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol 2005, 252:538-547.
13. Gallardo E., Rojas-Garcia R., de Luna N., et al. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001, 57:2136-2138.
14. Glover L., Brown R.H. Dysferlin in membrane trafficking and patch repair. Traffic 2007, 8:785-794.
15. Hermanová M., Zapletalová E., Sedlácková J., et al. Analysis of histopathologic and molecular pathologic findings in Czech LGMD2A patients. Muscle Nerve 2006, 33:424-432.
16. Hernandez-Deviez D.J., Martin S., Laval S.H., et al. Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Hum Mol Genet 2006, 15:129-142.
17. Ho M., Gallardo E., McKenna-Yasek D., et al. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 2002, 51:129-133.
18. Ho M., Post C.M., Donahue L.R., et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 2004, 13:1999-2010.
19. Huang Y., Laval S.H., van Remoortere A., et al. AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J 2007, 21:732-742.
20. Illa I., Serrano-Munuera C., Gallardo E., et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 2001, 49:130-134.
21. Illa I., De Luna N., Dominguez-Perles R., et al. Symptomatic dysferlin gene mutation carriers: characterization of two cases. Neurology 2007, 68:1284-1289.
22. Illarioshkin S.N., Ivanova-Smolenskaya I.A., Tanaka H. Clinical and molecular analysis of a large family with three distinct phenotypes of progressive muscular dystrophy. Brain 1996, 119:1895-1909.
23. Illarioshkin S.N., Ivanova-Smolenskaya I.A., Greenberg C.R., et al. Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. Neurology 2000, 55:1931-1933.
24. Katz J.S., Rando T.A., Barohn R.J., et al. Late-onset distal muscular dystrophy affecting the posterior calves. Muscle Nerve 2003, 28:443-448.
25. Klinge L., Laval S., Keers S., et al. From T-tubule to sarcolemma: damage-induced dysferlin translocation in early myogenesis. FASEB J 2007, 21:1768-1776.
26. Klinge L., Dean A.F., Kress W., et al. Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord 2008, 18:288-290.
27. Lennon N.J., Kho A., Bacskai B.J., et al. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem 2003, 278:50466-50473.
28. Linssen W.H., Notermans N.C., Van der Graaf Y., et al. Miyoshi-type distal muscular dystrophy. Clinical spectrum in 24 Dutch patients. Brain 1997, 120:1989-1996.
29. Liu J., Aoki M., Illa I., et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998, 20:31-36.
30. McNally E.M., Ly C.T., Rosenmann H., et al. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am J Med Genet 2000, 91:305-312.
31. McNeil A.K., Rescher U., Gerke V., et al. Requirement for annexin A1 in plasma membrane repair. J Biol Chem 2006, 281:35202-35207.
32. McNeil P.L., Terasaki M. Coping with the inevitable: how cells repair a torn surface membrane. Nat Cell Biol 2001, 3:E124-E129.
33. Mahjneh I., Passos-Bueno M.R., Zatz M. The phenotype of chromosome 2p-linked limb-girdle muscular dystrophy. Neuromuscul Disord 1996, 6:483-490.
34. Mahjneh I., Marconi G., Bushby K., et al. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul Disord 2001, 11:20-26.
35. Matsuda C., Kameyama K., Tagawa K., et al. Dysferlin interacts with affixin (beta-parvin) at the sarcolemma. J Neuropathol Exp Neurol 2005, 64:334-340.
36. Miyoshi K., Kawai H., Iwasa M. Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Seventeen cases in eight families including an autopsied case. Brain 1986, 109:31-54.
37. Nagashima T., Chuma T., Mano Y., et al. Dysferlinopathy associated with rigid spine syndrome. Neuropathology 2004, 24:341-346.
38. Nakagawa M., Matsuzaki T., Suehara M., et al. Phenotypic variation in a large Japanese family with Miyoshi myopathy with nonsense mutation in exon 19 of dysferlin gene. J Neurol Sci 2001, 184:15-19.
39. Nalefski E.A., Falke J.J. The C2 domain calcium-binding motif: structural and functional diversity. Protein Sci 1996, 5:2375-2390.
40. Nguyen K., Bassez G., Krahn M., et al. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol 2007, 64:1176-1182.
41. Okahashi S., Ogawa G., Suzuki M., et al. Asymptomatic sporadic dysferlinopathy presenting with elevation of serum creatine kinase. Typical distribution of muscle involvement shown by MRI but not by CT. Intern Med 2008, 47:305-307.
42. Paradas C., Llauger J., Diaz-Manera J., et al. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology 2010, 75:316-323.
43. Parton R.G. Caveolae and caveolins. Curr Opin Cell Biol 1996, 8:542-548.
44. Parton R.G., Way M., Zorzi N. Caveolin-3 associates with developing T-tubules during muscle differentiation. J Cell Biol 1997, 136:137-154.
45. Piccolo F., Moore S.A., Ford G.C., et al. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb-girdle muscular dystrophies. Ann Neurol 2000, 48:902-912.
46. Prelle A., Sciacco M., Tancredi L., et al. Clinical, morphological and immunological evaluation of six patients with dysferlin deficiency. Acta Neuropathol 2003, 105:537-542.
47. Raynal P., Pollard H.B. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1994, 1197:63-93.
48. Rosenberg N.L., Ringel S.P., Kotzin B.L. Experimental autoimmune myositis in SJL/J mice. Clin Exp Immunol 1987, 68:117-129.
49. Rowin J., Meriggioli M.N., Cochran E.J., et al. Prominent inflammatory changes on muscle biopsy in patients with Miyoshi myopathy. Neuromuscul Disord 1999, 9:417-420.
50. Selcen D., Stilling G., Engel A.G. The earliest pathologic alterations in dysferlinopathy. Neurology 2001, 56:1472-1481.
51. Seror P., Krahn M., Laforet P., et al. Complete fatty degeneration of the lumbar erector spinae muscles caused by a primary dysferlinopathy. Muscle Nerve 2008, 37:410-414.
52. Shaul P.W., Anderson R.G. Role of plasmalemmal caveolae in signal transduction. Am J Physiol 1998, 275:L843-L851.
53. Spuler S., Zabojszcza J., Straub V., et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann Neurol 2008, 63:323-328.
54. Suzuki N., Aoki M., Takahashi T. Novel dysferlin mutations and characteristic muscle atrophy in late-onset Miyoshi myopathy. Muscle Nerve 2004, 29:721-723.
55. Vilchez J.J., Gallano P., Gallardo E., et al. Identification of a novel founder mutation in the DYSF gene causing clinical variability in the Spanish population. Arch Neurol 2005, 62:1256-1259.
56. Weiler T., Bashir R., Anderson L.V., et al. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet 1999, 8:871-877.
57. Yamaji S., Suzuki A., Kanamori H., et al. Affixin interacts with alpha-actinin and mediates integrin signaling for reorganization of F-actin induced by initial cell-substrate interaction. J Cell Biol 2004, 165:539-551.